logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HR+ eBCa: mixed benefit for extended letrozole in NSABP B-42 trial

Failed to improve DFS, but may benefit women at high risk for recurrence.